Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial - Gianni, L; Pienkowski, T; Im, Y H; Roman, L; Tseng, L M; Liu, M C; Lluch, A; Staroslawska, E; de la Haba-Rodriguez, J; Im, S A (Lancet Oncol, 2012)
et al.